Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and stud ...
Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and stud ...
In oncology, Dr. Buell pointed to investigator-sponsored Phase II data in gastroesophageal cancer presented at AACR, noting: "median overall survival extended beyond 23 months in the immune primed ...
A federal sentencing on Tuesday of a Frederick man to seven years in prison was the first connected to an MS-13 gang killing ...
Operator: Ladies and gentlemen, thank you for joining, and welcome to the Innate Pharma First Quarter 2026 Business Update and Financial Results.
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive ...
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its Europe ...
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with ...
Registry analysis of 36,148 relapsing-onset cases showed lower annual DMT treatment probability in late-onset versus ...
Trial Met Dual Primary Endpoints of KCCQ and Maximal Exercise Performance With Consistent Positive Findings Across Key ...
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. The Terrorism Confinement Center (CECOT) stands in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results